These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 8301153)

  • 41. Is multiple sclerosis a disease that requires frequent beta interferon dosing?
    Durelli L
    J Neurol; 2004 Sep; 251 Suppl 4():IV13-24. PubMed ID: 15378303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial].
    Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ
    Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Betaseron: the new MS treatment.
    Kelley CL; Smeltzer SC
    J Neurosci Nurs; 1994 Feb; 26(1):52-6. PubMed ID: 8195651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Once weekly interferon beta for multiple sclerosis is superseded by higher and more frequent dosing.
    Blumhardt LD
    Int J Clin Pract Suppl; 2002 Sep; (131):9-16. PubMed ID: 12564807
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
    Pulicken M; Bash CN; Costello K; Said A; Cuffari C; Wilterdink JL; Rogg JM; Mills P; Calabresi PA
    Mult Scler; 2005 Apr; 11(2):169-74. PubMed ID: 15794390
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Interferon therapy of multiple sclerosis].
    Jensen D
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3142-5. PubMed ID: 10522481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?
    Durelli L; Oggero A; Verdun E; Isoardo G; Ricci A; Barbero P; Bergamasco B
    J Neurol Sci; 2000 Sep; 178(1):37-41. PubMed ID: 11018247
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations.
    Fieschi C; Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Galgani S; Paolillo A; Millefiorini E; Buttinelli C
    Mult Scler; 1995; 1 Suppl 1():S28-31. PubMed ID: 9345395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
    Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
    Becker RV; Dembek C
    J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Interferon-beta in treatment of relapsing multiple sclerosis].
    Hartung HP; Hohlfeld R
    Nervenarzt; 1994 Feb; 65(2):139-45. PubMed ID: 8164769
    [No Abstract]   [Full Text] [Related]  

  • 57. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis.
    Wroe SJ
    J Int Med Res; 2005; 33(3):309-18. PubMed ID: 15938592
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
    Gneiss C; Koudouovoh-Tripp PM; Ropele S; Gotwald T; Ehling R; Lutterotti A; Aichner F; Ladurner G; Eggers C; Schautzer F; Künz B; Millonig A; Aspeck E; Reindl M; Berger T; Fazekas F; Deisenhammer F
    Mult Scler; 2009 Dec; 15(12):1481-8. PubMed ID: 19965519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.